Laboratory Corp. of America Holdings plans to spin off its unit focused on clinical drug trials, a move that will create a new stand-alone company in the fast-growing contract-research sector.

Burlington, N.C.-based Labcorp unveiled the plan to separate its clinical-development business Thursday alongside its second-quarter results. Labcorp will continue its focus on its core diagnostic-testing business and will also retain two related pieces of its drug-development unit.

This post first appeared on wsj.com

You May Also Like

Debunking 3 Viral Rumors About the Texas Shooting

Rumors about the gunman and what had taken place spread widely online…

Zelenskyy and Biden to meet as Ukraine aid package stalls in Congress

WASHINGTON — Ukraine’s president will meet with President Joe Biden at the White House…

Manchin says Build Back Better is ‘dead.’ Here’s what he might resurrect.

WASHINGTON — Every morning at about 8:30, Sen. Joe Manchin receives a…

Tommy DeVito benched as Giants quarterback after brief run of success

EAST RUTHERFORD, N.J. — Tommy DeVito is out as the New York…